Reversal of insulin lipoatrophy by monocomponent insulin

Abstract

Lipoatrophy is a common complication over the site of insulin injection. Until fairly recently, no effective treatment was available for this unsightly complication. With the introduction of purified insulins (monocomponent, single-peak, rare-immunogenic) encouraging reports have appeared on the improvement and disappearance of lipoatrophy. This paper documents our initial experience with monocomponent (MC) Lente insulin (Novo, Copenhagen, Denmark), in reversing lipoatrophy caused by ordinary insulin injection in a female diabetic patient. The literature on this subject is briefly reviewed.